Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting

– Preclinical testing raises no safety concerns for MAGE A4 – – Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity – PHILADELPHIA, Pa. and OXFORD, United Kingdom, April 16, 2018 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy

Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018 (GLOBE NEWSWIRE) — Adaptimmune Therapeuticsplc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the upcoming AACR meeting at McCormick Place in Chicago, Illinois. Session, date,